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RNAs adopt diverse folded structures that are essential for function and thus play critical roles in cellular
biology. A striking example of this is the ribosome, a complex, three-dimensionally folded macromolecular
machine that orchestrates protein synthesis. Advances in RNA biochemistry, structural and molecular
biology, and bioinformatics have revealed other non-coding RNAs whose functions are dictated by their
structure. It is not surprising that aberrantly folded RNA structures contribute to disease. In this Review,
we provide a brief introduction into RNA structural biology and then describe how RNA structures function
in cells and cause or contribute to neurological disease. Finally, we highlight successful applications of
rational design principles to provide chemical probes and lead compounds targeting structured RNAs.
Based on several examples of well-characterized RNA-driven neurological disorders, we demonstrate how
designed small molecules can facilitate the study of RNA dysfunction, elucidating previously unknown roles
for RNA in disease, and provide lead therapeutics.Introduction
The genomic revolution of 1990s and 2000s brought about the
discovery of a wide variety of non-coding (nc) RNAs (Dunham
et al., 2012), leading to increased attention on understanding
their physiological functions. As with other biomolecules, the
function of RNA is closely linked to its three-dimensional struc-
ture, hence the rising interest in RNA structural biology (Figure 1).
Advances in the field culminated with remarkable results such as
the structures of bacterial (Ban et al., 2000; Schluenzen et al.,
2000; Schuwirth et al., 2005; Wimberly et al., 2000; Yusupova
et al., 2001) and eukaryotic (Ben-Shem et al., 2011) ribosomes.
As opposed to DNA’s double-stranded helix, RNA is most
often single stranded and thus folds onto itself to minimize its
free energy. RNA forms fully paired regions and non-canonically
paired regions such as hairpins, internal loops, bulges, multi-
branch loops, and pseudoknots that dictate higher-order folding
patterns (i.e., tertiary structure; Figure 2). Both secondary and
tertiary structural motifs serve as important recognition elements
guiding RNA-RNA and RNA-protein interactions. The impor-
tance of proper RNA folding for executing its function was recog-
nized early on from studies of rRNA and tRNA, which have highly
conserved structural organizations (Korostelev et al., 2006).
These structure-function relationships are not restricted to
non-coding RNAs. The majority of eukaryotic protein-encoding
RNAs (messenger RNA [mRNA]) undergo splicing from pre-
mRNA prior to translation (Li et al., 2007; Wang et al., 2008a),
and secondary structural elements in proximity of intron-exon
junctions can determine the exact location of intron excision
(Black and Grabowski, 2003; Buratti and Baralle, 2004; Buratti
et al., 2004; De Conti et al., 2013; Hiller et al., 2007; Shepard
and Hertel, 2008; Warf and Berglund, 2010). Moreover, the
choice of splicing sites based on exonic and intronic splicing
enhancers and silencers often depends on structural context
(Hiller et al., 2007).28 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.An important feature of RNA secondary structures is their dy-
namic nature such that multiple structures with similar free en-
ergies can be adopted, allowing for conformational switching.
Classic examples of large-scale structural rearrangements
include the ribosome’s structural changes that occur during
translation (Korostelev et al., 2006) and the shape-shifting func-
tions of riboswitches (Tucker and Breaker, 2005). Conforma-
tional changes upon interaction with other biomolecules are
essential for other functional RNAs as well (Baumstark et al.,
1997; Bugaut et al., 2012; Schultes and Bartel, 2000).
While proper folding of RNA is crucial to its normal function, it
is natural that misfolding leads to dysregulation of cellular pro-
cesses. In general, this pathology can arise either from loss of
function or from gain of function (Mirkin, 2007; La Spada and
Taylor, 2010). The former class of disease mechanisms usually
denotes a mutation in sites that are crucial for proper folding
and recognition of RNA by regulatory proteins. An altered folding
equilibrium leads to dysregulation of cellular processes. An
example are mutations in microtubule-associated protein tau
(MAPT aka tau) pre-mRNA that destabilize the hairpin structure
at the exon 10-intron 10 junction (Figure 7), which alters its inter-
action with U1 snRNP and causes deregulation of alternative
pre-mRNA splicing (Clark et al., 1998; Dumanchin et al., 1998;
Hutton et al., 1998; Jiang et al., 2000; Spillantini et al., 1998a;
Varani et al., 1999).
The gain-of-function class of disease mechanisms is triggered
by emergence of aberrantly folded RNA structural motifs in loca-
tions where they are not normally present (Mirkin, 2007; Reddy
and Housman, 1997; La Spada and Taylor, 2010). The most
common cause of such pathologies is genetic mutations that
lead to inclusions of pathogenic RNA fragments into gene tran-
scripts, such as those observed in nucleotide repeat expansion
disorders (La Spada et al., 1991; Verkerk et al., 1991). Depending
on the location of a repeat expansion, there are a variety of
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Figure 1. Number of High-Resolution Structures Containing RNA
Molecules Deposited in PDB Database per Year since 1991
Source: PDB database, http://www.rcsb.org (Berman et al., 2000).
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Reviewdownstream pathological mechanisms including misregulation
of the RNA’s splicing in which the mutation is found (cis-regula-
tion), production of non-functional or toxic proteins (Faustino
and Cooper, 2003; Feng and Xie, 2013; Licatalosi and Darnell,
2006), and sequestration of essential proteins that corrupts their
normal functions, which is typically processing of cellular RNAs
(trans-regulation) (Krzyzosiak et al., 2012; Ranum and Cooper,
2006; Todd and Paulson, 2010).
Here, we provide a brief introduction into RNA structural
biology, followed by a description of various RNA structures
that perform biological functions and/or trigger pathological cas-
cades in neurological diseases. Using several examples, we will
exemplify how cellular and animal models of diseases help to un-
derstand pathogenic mechanisms. Finally, we will discuss the
development and use of chemical tools (small molecules and
oligonucleotides) that normalize deregulated RNA function,
paving the road for potential RNA-targeting therapeutic interven-
tions in neurological diseases in a precise and selective manner.
Brief Overview of RNA Structure
In contrast to DNA, RNA adopts a variety of secondary and ter-
tiary structures. In base-paired regions, RNA adopts an A-type
helical conformation, which is characterized by less compact
folding than B-form DNA (11 base pairs per helical turn versus
10.5 bp, respectively), a deeper major groove, and a shallower
but wider minor groove. RNA’s 20 hydroxyl group dictates a
different sugar pucker, hydration state, and thermodynamic sta-
bility than DNA (Fohrer et al., 2006; Gyi et al., 1998). Hydrogen
bonding between nucleobases plays a crucial role in the
formation of RNA secondary and tertiary structures (SantaLucia
et al., 1992; Turner et al., 1987); only 6070% of bases in struc-
tured RNA form classic Watson-Crick contacts. Non-canonical
Hoogsteen (Hoogsteen, 1963) and wobble pairs (Crick, 1966;
Varani and McClain, 2000) are common in RNA and contribute
to the diversity of folding and function (Schroeder et al., 2004).
RNA folding is hierarchical in that primary sequence defines
secondary structure elements through nearest neighbor nucleo-tide effects (Brion and Westhof, 1997; Mathews et al., 1999,
2004). The most common secondary structures formed by
RNA strands are base-paired regions, stem-loops (hairpins), in-
ternal loops, bulges (Hermann and Patel, 2000; Mathews et al.,
1999, 2004), pseudoknots, kink-turns (Klein et al., 2001), com-
plex multibranch loops, and G-quadruplexes (Gellert et al.,
1962; Kim et al., 1991; Sundquist and Heaphy, 1993) (Figure 2).
These secondary structural motifs in turn can stabilize each other
through folding into more complex 3D patterns (Brion and West-
hof, 1997). It is noteworthy that both secondary and tertiary
structural elements can be dynamic and can interconvert de-
pending on the presence of proteins, electrolytes, and small mol-
ecules (Schroeder et al., 2004), altering RNA function (Baumstark
et al., 1997; Bugaut et al., 2012; Schultes and Bartel, 2000; Ser-
ganov et al., 2004).
The critical role of proper RNA folding for cellular functioning is
best exemplified by the central place of RNA in controlling pro-
tein synthesis—from gene expression to splicing and translation
of mRNA. Ribosomes and spliceosomes are comprised of highly
structured RNAmodules in complex with proteins (Figure 2B). At
the same time, pre-mRNAs and often mRNAs themselves
contain motifs that control efficiency of translation and splicing.
For example, G-quadruplex structures in 50 UTRs regulate trans-
lation ofmRNA in context-dependentmanner: either by inhibition
or by upregulation of cap-independent translation (Bugaut and
Balasubramanian, 2012).
RNA’s function is often dependent on its interactions with
other biomolecules and/or small molecules; those intermolec-
ular interactions are dependent upon acquisition of the proper
fold. These types of interactions, however, are far less studied
than secondary structure. For RNA-RNA interactions, the most
studied examples include ‘‘kissing’’ loop-loop and loop-stem
contacts that were found to regulate viral (Chang and Tinoco,
1994, 1997; Nicholson and White, 2014), prokaryotic (Brunel
et al., 2002; Marino et al., 1995), and eukaryotic RNAs (Sudar-
san et al., 2003; Wachter, 2010). Stabilization of a kink-turn
by long-distance contacts was found to be essential for the
folding and cellular function of prokaryotic RNA (Lilley,
2012; Schroeder et al., 2011), particularly for ribosomal RNA
(McPhee et al., 2014). Proteins can recognize their cognate
RNA-binding partners structure specifically, sequence specif-
ically, or via multiple modes of interaction (Serganov and Patel,
2008). The binding of proteins to RNA hairpins most often
occurs with the apical loop rather than the helical stem
region and resembles sequence-specific recognition of un-
structured ssRNA. Therefore formation of such loops is a
recurrent pattern of RNA folding that regulates interaction
with regulatory proteins. The presence of identical or similar
structural motifs in different RNAs engenders competition for
binding to regulatory proteins. Such equilibrium can serve, for
example, as a feedback loop for translational regulation by
controlling ribosome loading (Serganov and Patel, 2008). De-
pending on context, the binding of RNA structural motifs to
other biomolecules or structural domains can stabilize or desta-
bilize its tertiary structure. Modulation of structural stability by
small molecules underlies the biological function of folded
RNA motifs, such as riboswitches (Thore et al., 2006; Zhang
et al., 2010) and generally represents a potential strategy forNeuron 87, July 1, 2015 ª2015 Elsevier Inc. 29
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Figure 2. Secondary Structural Elements
Found in RNA and the 3D Structure of the
Ribosome
(A) Schematics of secondary structural elements in
RNA and representative three-dimensional struc-
tures from PDB. Nucleobases involved in Watson-
Crick base pairing or G-quadruplexes are colored
aquamarine and green; other bases are colored
magenta. PDB IDs for 3D structures: stem-loop,
PDB: 4TV0 (Zhang et al., 2014); internal loop, PDB:
2L8F (Lerman et al., 2011); bulge, PDB: 1AJL
(Luebke et al., 1997); pseudo-knot, PDB: 2A43
(Pallan et al., 2005); G-quadruplex, PDB: 2KBP
(Martadinata and Phan, 2009).
(B) Model of eukaryotic translation initiation
complex. Proteins and mRNA have been removed
for clarity. Individual RNA chains are represented
in different colors (Voigts-Hoffmann et al., 2012).
Downloaded and adapted from https://www.mol.
biol.ethz.ch/groups/ban_group/Initiation. Struc-
tures are rendered with PyMOL (Schro¨dingerLLC,
2010).
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Reviewtargeting structured RNAs therapeutically (see e.g., Childs
et al., 2002; Meisner et al., 2004).
As of 2015, sequence complementarity is the most common
way of targeting RNA. Mechanistically, an oligonucleotide hy-
bridizes with a target strand (forms antiparallel base-paired
duplex), thereby affecting its natural folding and interaction
with cognate partners or recruiting intracellular machinery that
cleaves the RNA (Bennett and Swayze, 2010). Such interaction,
however, depends on the thermodynamic and kinetic barrier of
unfolding the native conformation of both the target RNA and
the antisense oligonucleotide (Freier et al., 1986; Mir and South-
ern, 1999; Walton et al., 1999), which can be prohibitively high (Li
et al., 2008). Although there are RNA-binding proteins that facil-
itate RNA unfolding, the antisense-based strategy is still mostly
applicable to non-structured or weakly structured RNAs. Hence,
small molecules, which bind to folded RNA structures, e.g., loop
regions, represent a complementary means for controlling RNA
function to antisense oligonucleotides, as small molecules are
more apt to target folded RNAs.
Various methods have been developed to deduce RNA struc-
ture as understanding folding is foundational information that is
used to generate structure-function hypotheses (Figure 3).
Much of the activity in this area at present is deducing secondary
structure, or a map of paired and unpaired regions. For example,30 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.much of the secondary structure of the
ribosomewas deduced by using phyloge-
netic comparison and the conservation of
rRNA secondary structure (Figure 3A).
Importantly, these studies have been
used to assign the kingdoms of life and
to elucidate new ones (Gutell et al.,
1985; Noller and Woese, 1981). When
the crystal structures of the ribosome
became available, it was found that these
phylogenetic secondary structures were
highly accurate (Ban et al., 2000). When
it is not possible to complete phylogenetic
comparison because of a limited numberof available RNA sequences, secondary structure prediction
via free energyminimization is often used (Hofacker, 2003;Math-
ews et al., 1999, 2010; Zuker, 2003). The calculations provide the
predicted lowest free energy structure and a series of suboptimal
structures (Figure 3B). Alternatively, decomposition of RNA
sequence into basic elements and reconstruction of the 3D
folding based on known patterns for these elements proved to
be helpful in spotting non-canonical base-pairs interactions (Par-
isien and Major, 2008). These approaches can be accurate for
smaller RNAs, but accuracy diminishes as the size of an RNA in-
creases. For larger RNAs, secondary structures can be deduced
by using a combination of prediction and experimental con-
straints generated by structure probing (Mathews et al., 1999,
2010). RNA structure has been probed both in vitro and in cellulo
with dimethyl sulfate (DMS) (Lempereur et al., 1985; Mathews
et al., 2004; Tijerina et al., 2007; Wells et al., 2000), selective
20-hydroxyl acylation analyzed by primer extension (SHAPE)
(Kwok et al., 2013; Merino et al., 2005) (Figure 3C), and in a vari-
ety of nuclease protection assays (Ehresmann et al., 1987). This
synergistic approach has been quite accurate to decode RNA
structures, such as rRNA, viral RNAs, and others (Ding et al.,
2014; Mathews et al., 2004; Merino et al., 2005; Weeks, 2010;
Wilkinson et al., 2006). Likewise, methods have been developed
to combine free energy minimization and sequence alignment
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Figure 3. RNA Structure Prediction and
Chemical Mapping
(A) Phylogenetic analysis of three sequences
highlighting conserved base paired regions
(green) and mismatches (yellow).
(B) Two alternative structures predicted for
sequence 3 by RNAstructure (Reuter and Math-
ews, 2010). Red arrows indicate locations of
reactive hydroxyl groups identified by 20-hydroxyl
acylation and primer extension (SHAPE). Blue
asterisks indicate A and C residues susceptible for
methylation by dimethyl sulfate (DMS).
(C) Chemical reactions underlying SHAPE and
DMS mapping. 1M7, 1-methyl-7-nitroisatoic an-
hydride.
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Review(Bernhart et al., 2008; Mathews and Turner, 2002). Although sec-
ondary structure can provide important frameworks to develop
hypotheses about the role of RNA structure, information about
tertiary structure would also be helpful. Predictive approaches,
in addition to the well-established experimental approaches
such as X-ray crystallography and nuclear magnetic resonance
(NMR) spectroscopy, are being developed to quickly and accu-
rately decipher three-dimensional structure. It is likely that a
combination of prediction and experiment, such as has been
shown for secondary structure prediction, will allow for accurate
models of RNA three-dimensional structure to be generated
quickly (Sripakdeevong et al., 2014).
The Roles of Structured RNAs in Cellular Biology
A great variety of functional, non-coding RNAs regulate neuronal
development and physiological function (Qureshi and Mehler,
2012). Little is currently known, however, about the role of ter-
tiary folding in most of these RNAs. Large non-coding RNAs
(lncRNAs) are attracting attention due to the regulatory role
they play in gene expression (Bond et al., 2009; Faghihi et al.,
2008; Khalil et al., 2009; Ng et al., 2013; Tsai et al., 2010;Wahles-
tedt, 2013). Multiple enhancer RNA structures facilitate recruit-
ment of CREB binding protein (CBP) to cognate genes and
thereby regulate activity-dependent gene transcription in neu-
rons, which underlies neuronal development and synaptic plas-
ticity (Kim et al., 2010). Most of what is known about lncRNAs’
mechanismof action is antisense base-pairingwith target genes,
formation of DNA-RNA triplexes (Geisler and Coller, 2013), andNeurallosteric recruitment of gene-repressing
peptides to their target genes (Wang
et al., 2008b) (Figure 5A).
It is estimated that >90% of human
pre-mRNA is alternatively spliced, and
this process is highly tissue specific
(Wang et al., 2008a). Many splicing regu-
lators (proteins and ribonucleoproteins
[RNPs]) apparently control their own syn-
theses (Li et al., 2007), providing impor-
tant feedback loops. Some examples of
splicing regulation by RNA-binding pro-
teins and secondary structural elements
are provided below. Formore rigorous re-
view of splicing regulation by pre-mRNAsecondary structure, please see De Conti et al. (2013) and
Warf and Berglund (2010).
The neuro-oncological ventral antigen (NOVA) family of pro-
teins regulates alternative splicing in neurons (Ule et al., 2006).
Particularly, they control inhibitory neurotransmission in synap-
ses by processing pre-mRNAs of glycine receptor subunit a2
(GlyRa2), GABAA receptor subunit g2 (GABAARg2), gephyrin,
and Jnk2, among at least 50 other neuronal genes (Figure 4C)
(Musunuru and Darnell, 2004; Ule et al., 2006). The sequence
specificity of the RNA-binding K-homology (KH) domains of
NOVA-1 protein was established by various methods such as
systematic evolution of ligands by exponential enrichment
(SELEX) (Musunuru and Darnell, 2004), UV cross-linking and
immunoprecipitation (CLIP) (Ule et al., 2003), and individual-
nucleotide resolution (i)CLIP (Sugimoto et al., 2012). NOVA-1
binds multiple repeats of UCAU intronic sequence in the
GlyRa2 and GABAARg2 pre-mRNAs. The binding of NOVA-1
KH-13 domains to RNA was studied extensively (Teplova
et al., 2011) (Figure 4B), suggesting that multivalent binding
of RNA-targeting motifs reorganizes the architecture of the
RNA’s fold (Nicastro et al., 2015). Blockade of KH domains by
antibodies disrupts NOVA-RNA interactions and causes neuro-
degeneration in patients with paraneoplastic opsoclonus-myoc-
lonus-ataxia (POMA) (Luque et al., 1991).
Proteins from muscleblind-like family (MBNL), regulators of
alternative pre-mRNA splicing, bind RNA with four zinc finger
(ZnF) domains (Konieczny et al., 2014), determining which
RNAs are MBNL substrates. MBNL1, the most studied memberon 87, July 1, 2015 ª2015 Elsevier Inc. 31
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Figure 4. Structure of Splicing-Regulating
Proteins MBNL1 and NOVA in Complex with
RNA Recognition Elements and Location of
Splice Sites in Corresponding mRNAs
(A) Fragment of MBNL1 complexed with a canonical
recognition sequence of RNA, GCUGU, PDB: 3D2S
(Teplova and Patel, 2008).
(B) Fragment of NOVA1 complexed with a stem-loop
of a cognate RNA, PDB: 2ANN (Teplova et al., 2011).
(C) Locations of RNA recognition sites for MBNL1
and NOVA1, relative to alternatively spliced exons.
Representative mRNA substrates are listed next to
arrows denoting the RNA recognition element loca-
tion (Konieczny et al., 2014; Ule et al., 2006). cTNT,
cardiac troponin T;CLCN1, muscle-specific chloride
ion channel 1; GABRG2, g-aminobutyric acid
(GABA) receptor g2; GLRA2, glycine receptor a2;
INSR, insulin receptor; KCNMA1, potassium large
conductance calcium-activated channel, subfamily
M, a1; MBNL1, muscleblind-like protein 1; NOVA1,
neuro-oncological ventral antigen 1.
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Reviewof the family, regulates alternative splicing of muscle-specific
chloride ion channel (CLCN1) (Mankodi et al., 2002), insulin re-
ceptor (INSR) (Savkur et al., 2001), bridging integrator 1 (BIN1)
(Fugier et al., 2011), cardiac troponin T (cTNT) (Philips et al.,
1998), and several hundred other splicing events (Wang et al.,
2012) (Figure 4C). By binding to a hairpin formed by canonical
YGCY recognition sequence in cTNT pre-mRNA, MBNL1 trig-
gers unwinding of the structure and subsequent splicing (Ko-
nieczny et al., 2014) (Figure 4A). Transcriptome-wide analysis re-
vealed additional extranuclear roles of MBNL proteins such as
targetingmRNAs to the rough endoplasmic reticulumandcellular
membrane and regulation of local translation (Wang et al., 2012).
RNA structure can also regulate translation by controlling ribo-
somal loading. Overexpression of ribosomal proteins can cause
binding tomRNA outside the context of a ribosome, thereby pre-
venting translation. One example is L1 protein, the largest pro-
tein in the large ribosome subunit, which binds to its own
mRNA (Tishchenko et al., 2008) by recognizing a domain that re-
sembles rRNA fold (Nevskaya et al., 2005).
Asmentioned above, a definedRNA structure also functions in
the cellular delivery of proteins. Delivery of the translation com-
plex to endoplasmic reticulum membrane is critical for matura-
tion and targeting of secretory and membrane-bound proteins.
This process is regulated by the signal recognition particle
(SRP), a GTP-dependent ribonucleoprotein complex (Doudna
andBatey, 2004). A U-turn forming Alu domain of SRPRNAplays
the central role in assembly of the complex and binding to ribo-
some (Halic et al., 2004) and to SRP receptor in the endoplasmic
membrane (Ataide et al., 2011) (Figure 5B). Mechanistic aspects
of SRP function and the role of SRP RNA have been reviewed
recently (Akopian et al., 2013).
Secondary structure elements in introns of mRNAs and in 50
and 30 UTRs have been identified as important markers for32 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.cellular splicing machinery (Buratti and
Baralle, 2004), mRNA trafficking (e.g.,
axonal and dendritic transport [Gomes
et al., 2014; Jung et al., 2012]), and transla-
tion initiation (Hughes, 2006). Stem-loopsthat contain canonical nucleotide sequences in their apical
loop are markers for NOVA-1 recruiting. Notably, relative posi-
tioning of these structures determines NOVA-1-dependent skip-
ping or inclusion of a particular exon (Figure 4) (Ule et al., 2006),
similarly to MBNL-regulated mRNAs (Wang et al., 2012).
A stem-loop (with the canonical recognition pattern) in the 50
UTR of ferritin-H and ferritin-L mRNA regulates expression of
iron storage proteins (Thomson et al., 1999). The apical loop of
the hairpin serves as a sensor for intracellular level of iron, hence
the motif is called iron-responsive element (IRE). Interestingly,
similar motifs were found in other mRNAs (Piccinelli and Sa-
muelsson, 2007), including amyloid precursor protein (APP)
(Rogers et al., 2002, 2011) and a-synuclein (Friedlich et al.,
2007; Olivares et al., 2009). a-Synuclein is the prime toxic protein
in Parkinson’s disease (PD) and other a-synucleinopathies (Lee
and Trojanowski, 2006; Singleton et al., 2003). It forms fibrils
that propagate across neurons in the brain and accumulate in
Lewy bodies and Lewy neurites (Spillantini et al., 1997, 1998b).
The expression level of a-synuclein is an important determinant
in the rate of its fibrillization and neurotoxicity (El-Agnaf et al.,
2006). Thus, downregulating its expression is expected to be
beneficial. The translation of some a-synuclein isoforms is regu-
lated by a hairpin structure that is similar to the IRE in the 50 UTR
and was found to be iron dependent (Febbraro et al., 2012).
Other common functional elements of structured mRNAs
include three-way multibranch loops (junctions) (de la Pen˜a
et al., 2009), kink-turns (McPhee et al., 2014), hairpins, and
G-quadruplexes (Bugaut and Balasubramanian, 2012). G-quad-
ruplexes are often found in non-coding regions of mRNAs and
provide structural domains recognized by functional proteins,
e.g., fragile X mental retardation proteins (FMRPs) (Melko
and Bardoni, 2010). The structure selectivity of FMRP is dif-
ferent from other RNA-binding proteins containing KH domains
A B
mRNA
SRP
ribosome
ER
cytosol
nascent
protein
lncRNA
DNA
protein C
DNA
RNA Pol II
CoTC pre-mRNA
Figure 5. Representative Functions of Structured Non-coding RNAs in Cells
(A) Schematic of a triplex formed between DNA and lncRNA that allosterically recruits gene-regulating proteins.
(B) Simplified representation of SRP RNA’s role in targeting membrane proteins to the endoplasmic reticulum (ER) for their proper folding.
(C) Schematic of co-transcriptional cleavage element regulating transcription termination of the b-globin gene. CoTC, co-transcriptional cleavage element;
ER, endoplasmic reticulum; RNA Pol II, RNA polymerase II; SRP, signal recognition particle.
Neuron
Review(Siomi et al., 1993), as the RGG box binds G-quadruplex-con-
taining mRNAs (including FMR1 mRNA that encodes FMRP)
(Darnell et al., 2001). At the same time, another domain of
FMRP binds between two ribosomal subunits and directly com-
petes with eukaryotic translation elongation factors 1 alpha
and 2 (eEF1A and eEF2) and aminoacyl-tRNA (Chen et al.,
2014). Thereby, FMRP temporarily suspends the translation of
the target mRNA and transports it from the nucleus to synapses.
Phosphorylation of FMRP, due to external stimuli, decreases
affinity of FMRP to the ribosome and de-represses transcription
of its target mRNAs. Taken together, FMRP regulates activity-
dependent local mRNA translation and influences cognitive pro-
cesses at the cellular level (Antar et al., 2006).
Additional example of RNA-binding proteins essential for RNA
transport is the Staufen family (St Johnston et al., 1991). They
regulate delivery of mRNA and thereby play a central role in
cellular differentiation and dendritic transport (Tang et al., 2001).
Staufen proteins bind and stabilize base-paired sites in RNA
secondary structures, which are abundant in 30 UTR of mRNAs
(Sugimoto et al., 2015). Structural basis of double stranded (ds)
RNAstemrecognitionbyStaufenandotherRNA-bindingproteins
has been recently reviewed (Gleghorn and Maquat, 2014).
Conversion of adenosine to inosine (i.e., RNA editing) is an
important process in regulating splicing patterns of membrane
receptors and ion channels, which has been proposed to be tar-
geted therapeutically (Gott and Emeson, 2000; Morabito and
Emeson, 2009). In general, it is the tertiary fold of the mRNA
that determines the editing pattern (Bhalla et al., 2004; Enstero¨
et al., 2009; Rieder et al., 2013; Tian et al., 2011). Alternative
editing of the serotonin receptor HTR2C pre-mRNA plays a
major role in Prader-Willi syndrome pathology, a genetic disease
associated with expression of serotonin receptor isoform with
reduced constitutive activity and decreased efficiency of
coupling to G protein (Morabito et al., 2010).
Pathogenic RNA Structures in Neurological Diseases:
How Can RNA Structure Cause Disease?
Many of the functional secondary structural elements described
above can spontaneously emerge as pathogenic agents as a
result of point mutations, sequence deletions, and expansions.
These newly formed, mutated RNA motifs interfere with normalinteractions and initiate pathologic processes in cells. Examples
of such gain of function include sequestration of RNA-binding
proteins, activation of cryptic splicing sites, dysregulation of
site-specific RNA editing by adenosine deaminase acting on
RNA (ADAR), and formation of pseudo internal ribosome entry
sites (IRES) and subsequent cap-independent translation (Mir-
kin, 2007), i.e., repeat associated non-ATG (RAN) translation
(Zu et al., 2011). Interestingly, broad-scale proteomics and tran-
scriptome studies have shown that many peptides are produced
without canonical AUG start codons (Lee et al., 2012; Slavoff
et al., 2013; Stern-Ginossar et al., 2012). Thus, the biological
implications of understanding RAN translation are not restricted
to pathologic RNA structures.
Several causes of pathogenic RNA folding are known. In fact,
most often it is the development of pathology that reveals the
functional role of particular RNA structural motif. SNPs are a
common cause of abnormal RNA folding. Mutations of a single
nucleobase can change conformational stability of a secondary
structure element, potentially disrupting a delicate equilibrium
of RNA-protein interaction networks and causing downstream
pathology. One of the most studied examples is MAPT (tau)
mRNA, vide infra. For more detailed discussion on the role of
mutated pre-mRNA secondary structures in splicing deregula-
tion, see Warf and Berglund (2010).
Retrotransposon insertions into intronic regions of pre-
mRNAs contribute to protein isoform diversity by activation of
cryptic splicing sites. This mechanism plays important roles
in evolution, brain development, and cellular differentiation
but often also contributes to genetic diseases (Baillie et al.,
2011; Deininger and Batzer, 1999). For example, the structured
retrotransposon Alu element of 7SL RNA plays a crucial role
in the assembly of SRPs (Figure 5B). The Alu motif is the
second most abundant retrotransposon in the human genome;
its more than one million copies comprise roughly 11% of
the entire genome (Lander et al., 2001). Insertions of Alu
elements into intronic regions can activate cryptic exons, which
leads to formation of unnatural protein isoforms (Pagani and
Baralle, 2004; Vervoort et al., 1998). Abnormal recombination
driven by Alu elements can also result in deletion of large
gene fragments (Iida et al., 2012; Nakayama et al., 2010),
and co-migration of other pathologic RNA fragments causesNeuron 87, July 1, 2015 ª2015 Elsevier Inc. 33
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Figure 6. Targeting Expanded Repeating
RNAs that Cause or Contribute to
Microsatellite Disorders
(A) Two-dimensional representation of a hairpin
with multiple internal loops formed by expanded
microsatellite repeats with examples of repetitive
nucleotide sequences.
(B) Three-dimensional structure of r(CGG)3 frag-
ment, PDB: 3SJ2 (Kumar et al., 2011b). Coloring
scheme is the same as for Figure 2.
(C) Targeting repetitive structural elements with
small molecules, modularly assembled multivalent
binders with increased affinity and selectivity, and
in cellulo oligomerization as an ultimate strategy for
precise targeting of expanded RNA repeats.
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Reviewpropagation of associated pathology (Clark et al., 2004; Kurosaki
et al., 2009, 2012).
In the case of microsatellite repeat expansion disorders,
particular DNA oligonucleotide fragments (repeated sequences)
fold into stable hairpins, thereby causing strand ‘‘slipping’’ dur-
ing replication, repair, and recombination. This causes formation
and elongation of such repetitive fragments (Gacy et al., 1995;
Lo´pez Castel et al., 2010). Transcription yields the correspond-
ing single-stranded RNA that contains the expanded repeated
sequence, which is aberrantly folded due to the presence of
additional secondary structural elements (Figures 6A and 6B).
Once stably incorporated into DNA sequence, expanded re-
peats are evenmore likely to fold into abnormal structures, which
leads to gradual augmentation of pathology with age and in sub-
sequent generations, a phenomenon known as repeat instability
(Kovtun andMcMurray, 2008; Liu et al., 2010; Lo´pez Castel et al.,
2010).
Microsatellite Repeat Expansion Disorders
As described above, RNA-binding proteins have sequence
and structural binding preferences (Serganov and Patel,
2008). Some expanded repeats mimic these recognition ele-
ments and sequester proteins or RNA-processing cellular
machinery away from their normal RNA targets (Echeverria
and Cooper, 2012). Most often, GC-rich oligonucleotide se-
quences form expanded repeats: r(CAG)exp (where ‘‘exp’’ de-
notes an expanded repeating sequence) (Mangiarini et al.,
1996), r(CUG)exp (Brook et al., 1992), r(CCUG)exp (Liquori et al.,
2001), r(CGG)exp (Verkerk et al., 1991), and r(G4C2)exp
(DeJesus-Hernandez et al., 2011) (Figure 6A). Downstream path-
ogenic processes in microsatellite repeat expansion disorders
include deregulation of alternative pre-mRNA splicing (Philips
et al., 1998; Ranum and Cooper, 2006), formation of insoluble
nucleoprotein inclusions (foci) (Taneja et al., 1995), and RAN
translation (Zu et al., 2011) into toxic peptides (reviewed in Krzy-
zosiak et al., 2012; Shin et al., 2009; Todd and Paulson, 2010). If a34 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.repeat expansion is located in a coding re-
gion, toxic proteins with a polypeptide
chain encoded by the corresponding
triplet codon are produced (La Spada
and Taylor, 2010).
Two secondary structure elements are
formed by expanded repeats: hairpinscontaining periodically repeating internal loops (Figure 6B) and
G-quadruplexes. The latter is formed only by extremely G-rich
sequences, e.g., r(G4C2)exp (Reddy et al., 2013). Some non-nat-
ural trinucleotide repeats (r(AGG) and r(UGG)) also fold into
G-quadruplexes when expanded sufficiently (Sobczak et al.,
2010). The central role of aberrant RNA folding in its gain of func-
tion has been extensively reviewed (Mirkin, 2007; Pearson, 2011;
La Spada and Taylor, 2010). It is worth keeping inmind, however,
that it is nearly impossible to delineate the confounding role of
sheer size of expanded repeats (and associated increase in stoi-
chiometry of protein binding) from the role of their folding in RNA
pathology.
r(CUG)exp and r(CCUG)exp: Myotonic Dystrophy
Types 1 and 2
Formation of hairpins by r(CUG)exp and r(CCUG)exp, with multiple
13 1 and 23 2 internal loops in the stem, leads to the develop-
ment of myotonic dystrophy (DM) types 1 and 2, respectively.
DM1 is an autosomal dominant disease that is themost common
form of adult muscular dystrophy with an incidence of 1:8,000
(Brook et al., 1992). DM2 is also autosomal dominant but with
less severe symptoms than DM1 (Liquori et al., 2001). While
r(CUG)exp (DM1) resides in the 3
0 UTR of dystrophia myotonica
protein kinase (DMPK) mRNA, r(CCUG)exp (DM2) is located in
the first intron of CCHC-type zinc finger nucleic acid binding pro-
tein (CNBP aka ZNF9) mRNA. There is overwhelming experi-
mental evidence for protein sequestration as the major source
of pathology in both diseases (Fardaei et al., 2002; Kanadia
et al., 2006; Lu et al., 1999; Miller et al., 2000). MBNL proteins
are sequestered in nuclear foci via dynamic interaction with
r(CUG)exp or r(CCUG)exp (Fardaei et al., 2002; Mankodi et al.,
2001). In DM1, sequestration leads to decreased nucleocyto-
plasmic transport and downregulation of DMPK. More impor-
tantly, protein sequestration deregulates alternative splicing of
MBNL1- and MBNL2-dependent mRNAs (Charizanis et al.,
2012; Ho et al., 2004; Philips et al., 1998). Inclusion of pathologic
repeats in the native DMPK locus or a heterologous gene in
Neuron
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type, underscoring the central role of expanded repeat structure
in DM pathology (Mankodi et al., 2000; Monckton et al., 1997). In
addition to DM1, r(CUG)exp repeats are also characteristic of spi-
nocerebellar ataxia type 8 (SCA8) (Daughters et al., 2009), and
Huntington’s disease-like HDL2 (Rudnicki et al., 2007), where
they also sequester MBNL proteins in nuclear foci and deregu-
late MBNL-dependent pre-mRNA splicing.
A great deal of effort has been expended to determine how
MBNL proteins recognize r(CUG)exp and r(CCUG)exp, hence
various studies into their secondary structures. Formation of
r(CUG)exp and r(CCUG)exp hairpins has been confirmed in vitro
(Gacy et al., 1995), and the stability of the RNA generally in-
creases with repeat length (Napiera1a and Krzyzosiak, 1997;
Tian et al., 2000). Importantly, these studies indicate that the
hairpin stem contains non-canonically paired loops. A number
of structures of r(CUG) repeat-containing constructs have been
deposited in the Protein Data Bank (PDB) (Berman et al.,
2000), which confirms formation of an imperfectly paired stem.
The structures resemble an A-form helix but with deeper and
narrower major grooves, reminiscent of A-form DNA. Further,
some structures indicate loop dynamics (Coonrod et al., 2012;
deLorimier et al., 2014; Kiliszek et al., 2009; Kumar et al.,
2011a; Mooers et al., 2005; Tamjar et al., 2012). The X-ray struc-
ture of r(CCUG)3 was recently published, providing insight into
the structures of 50UC30/30CU50 present in the hairpin stem
(Childs-Disney et al., 2014). In contrast to A-formRNA, the helical
axis of r(CCUG)3 was bent by 18.5
 at the central internal loop.
Major and minor groove widening and narrowing, respectively,
was observed in the internal loops. Molecular dynamics simula-
tions suggested that 50CU/30UC internal loops exist in a dynamic
equilibrium between two conformations (Childs-Disney et al.,
2014).
A complex of tetramericMBNL1 bound to amodel RNA recog-
nition site has been characterized by X-ray crystallography (Te-
plova and Patel, 2008) (Figure 4A); a complex of two MBNL1
zinc fingers with two single-stranded RNAs has also been refined
from X-ray crystallographic data (Teplova and Patel, 2008). The
specificity of MBNL1 binding to imperfect (with multiple U 3 U
or CU 3 UC internal loops) rather than to fully base-paired
stem-loop was demonstrated experimentally (Kino et al., 2004;
Warf and Berglund, 2007). Taken together, these structural
studies suggest that once bound to the DM1 and DM2 hairpins,
MBNL1 unwinds their helical structure, which facilitates multiva-
lent binding (Fu et al., 2012; Konieczny et al., 2014).
In addition to splicing deregulation, r(CUG)exp also recruits ri-
bosomes and initiates RAN translation (Zu et al., 2011). This phe-
nomenon was initially characterized in cells and tissue derived
from SCA8 and DM1 patients. It was found that repeat length
is a critical determinant of enabling RAN translation (Zu et al.,
2011). These studies suggested that hairpins formed by
r(CUG)exp serve as internal ribosome entry sites (IRESs) and
CUG binding protein (CUGBP1) acts as IRES translation-associ-
ated factor. After initial discovery of the stable hairpin structure
formed by r(CUG)exp, experiments on other expanded trinucleo-
tide repeats showed that the hairpins are formed by the vast
majority (Sobczak et al., 2003), although not all trinucleotide se-
quences (Sobczak et al., 2010).r(CGG)exp in FXS, FRAXE, and FXTAS
Expanded r(CGG) repeats form stable hairpins in the 50 UTR of
fragile X mental retardation mRNA (FMR1), which encodes frag-
ile Xmental retardation protein (FMRP), a key regulator of protein
expression and trafficking in CNS. The repeats are major molec-
ular pathogens in fragile X-associated tremor ataxia syndrome
(FXTAS) (Hagerman et al., 2001; Jacquemont et al., 2003), fragile
X syndrome (FXS) (Pieretti et al., 1991; Verkerk et al., 1991), and
fragile XE syndrome (FRAXE) (Gecz et al., 1996; Knight et al.,
1993). In FXTAS, a pre-mutation allele of r(CGG)exp (55200 re-
peats [Jacquemont et al., 2003]) initiates RAN translation, lead-
ing to the premature start of FMR1 translation and production
of non-functional FMRP with an N-terminal polyglycine chain
(Todd et al., 2013). The repeats also bind and sequester various
RNA-binding proteins in nuclear foci: heterogeneous ribonucleo-
protein particle (hnRNP), MBNL1 (Iwahashi et al., 2006),
DiGeorge syndrome critical region gene 8 protein (DGCR8) (Sell-
ier et al., 2013), and Src-associated in mitosis, 68 kDa protein
(Sam68) (Greco et al., 2006; Sellier et al., 2010), causing dereg-
ulation of alternative pre-mRNA splicing andmicroRNA process-
ing (Arocena et al., 2005). Interestingly, stabilizing interruptions
within the premutation allele of r(CGG)exp, such as AGG inserts,
lead to branching of the hairpin structure. It was suggested that
this branching precludes toxicity (Napiera1a et al., 2005).
FXS is caused by r(CGG) expansions of lengths >200, or the
full mutation allele (Pieretti et al., 1991; Verkerk et al., 1991).
Although it was known that the expansion leads to silencing of
the FMR1 gene and hence loss of FMRP, the exact mechanism
of silencing was only recently elucidated. Specifically, an RNA-
DNA hybrid forms between r(CGG)exp and the FMR1 gene,
silencing transcription via induction of chromatin remodeling
(Colak et al., 2014). Stabilization of the r(CGG)exp hairpin by a
small molecule prevents RNA unfolding and subsequent binding
to FMR1 promoter region thus inhibiting gene silencing, vide
infra.
Other hairpin-forming repeats include r(CAG)exp, which ismost
often located in coding regions and produce toxic polyglut-
amine-containing proteins as observed in Huntington’s disease
(HD) (MacDonald et al., 1993). It was also suggested, however,
that r(CAG)exp contributes to HD toxicity directly. Like r(CUG)exp,
r(CAG)exp sequesters MBNL1 and binds with similar affinity
(Mykowska et al., 2011). In addition, r(CAG)exp appears to
sequester nucleolin to deregulate nuclear transport, recruit
Dicer, and initiate RAN translation (Nalavade et al., 2013). In
HD, the splicing factor SRSF6 binds to r(CAG)exp, which
correlates with the observed deregulation of HTT (huntingtin)
splicing in which exon 1 is aberrantly included. Exon 1 is followed
by a premature stop codon, hence producing truncated
huntingtin (protein), which is the major component of nuclear
inclusions in HD (Sathasivam et al., 2013). The N terminally trun-
cated huntingtin has been shown to be highly pathogenic in a
mouse model (Mangiarini et al., 1996). Together, these findings
suggest that aberrant splicing might be the major pathogenic
cause of HD.
RNA Hairpins and G-Quadruplexes in ALS/FTD
G-rich strands of RNA and DNA can form G-quadruplex
structures (Sundquist and Klug, 1989). The pathogenic
expanded hexanucleotide r(G4C2)exp in C9ORF72, associatedNeuron 87, July 1, 2015 ª2015 Elsevier Inc. 35
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Figure 7. Secondary Structure of the
Hairpin that Regulates the Alternative
Splicing of Exon 10 in Microtubule-
Associated Protein Tau Pre-mRNA
Hairpin mutants are arranged in order of
decreasing thermodynamic stability (left to right),
according to published data (Donahue et al., 2006;
Varani et al., 1999). Mutations increasing the
number of intramolecular hydrogen bonds are
highlighted in blue; mutations decreasing the
number of Watson-Crick base pairs are high-
lighted in red. Exon nucleotides are highlighted in
green. The bulge targeted by small molecules is
boxed in red in thewild-type (WT) hairpin (seemain
text for details). Mutations, which deregulate
normal splicing of MAPT leading to frontotemporal
dementia and Parkinsonism associated with
chromosome 17 (FTDP-17), are underlined.
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Reviewwith amyotrophic lateral sclerosis and frontotemporal dementia
(or c9ALS/FTD) (Akimoto et al., 2014; DeJesus-Hernandez
et al., 2011), folds into two structures that are in equilibrium: a
hairpin displaying periodically repeating G-rich internal loops
and a G-quadruplex (Haeusler et al., 2014; Reddy et al., 2013;
Su et al., 2014). r(G4C2)exp is the most frequent cause of familial
amyotrophic ALS/FTD (Akimoto et al., 2014; DeJesus-Hernan-
dez et al., 2011). Akin to other repeat expansions, r(G4C2)exp
forms ribonuclear foci that sequester RNA-binding proteins, de-
regulates gene expression (Donnelly et al., 2013; Haeusler et al.,
2014; Xu et al., 2013), and initiates RAN-translation (Ash et al.,
2013; Donnelly et al., 2013). Formation of RNA-DNA hybrids
(R-loops) underlies dysregulation of gene expression by
r(G4C2)exp via different mechanisms (Haeusler et al., 2014;
Wang et al., 2015). The RAN translation products of C9ORF72
are dipeptide repeat (DPR) proteins: poly(GlyPro), poly(GlyArg),
poly(GlyAla), poly(ProAla), and poly(ProArg). Among them, argi-
nine-rich products appear to be the most toxic (Mizielinska
et al., 2014). DPR proteins penetrate cellular membranes, accu-
mulate in nucleoli, and impair pre-mRNA splicing and biogenesis
of rRNA (Kwon et al., 2014; Mizielinska et al., 2014; Xu et al.,
2013). Replacement of r(G4C2)exp by synonymous sequences
encoding poly(GlyArg) and poly(ProArg) proteins causes neuro-
degeneration in aDrosophilamodel of ALS/FTD, which suggests
a prevalent role for RAN translation in r(G4C2)exp-mediated
pathology (Mizielinska et al., 2014).
Interestingly, C9ORF72 is bidirectionally transcribed; the anti-
sense strand contains r(G2C4)exp, which also forms nuclear foci
and toxic RAN peptides (Gendron et al., 2013; Zu et al., 2013).
Moreover, recent data suggest its importance in c9ALS/FTD
pathogenesis, which should be taken into account in therapeutic
treatment strategies (Lagier-Tourenne et al., 2013). Such consid-
erations of both sense and antisense strands to toxicity are not
unique to c9ALS/FTD as shown by the Ranum laboratory
(Daughters et al., 2009).
Tauopathies: Tau Mutations Affect Stability of RNA
Structure at Exon-Intron Junction
The stability of other RNA hairpins, not associated with repeat
expansions, regulates normal alternative pre-mRNA splicing.
For example, a stable stem-loop hairpin structure between
exon 10 and intron 10 of MAPT dictates exon 10 inclusion or
exclusion (Hutton et al., 1998; Jiang et al., 2000) (Figure 7). Mu-36 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.tations that destabilize the hairpin lead to more frequent inclu-
sion of the exon and increased production of a longer isoform
of tau protein that contains four microtubule-binding domains
(Liu and Gong, 2008). Overproduction of this mutant tau protein
leads to frontotemporal dementia and Parkinsonism associated
with chromosome 17 (FTDP-17) (Goedert et al., 1998). In
contrast, stabilization of the hairpin leads to exon skipping
(Donahue et al., 2006). NMR structural data confirmed that
mutation of +3 G residue to A severely affects the conformation
of the stem-loop (Varani et al., 1999), which regulates access of
U1 snRNP to the splice site and exon inclusion (Jiang et al.,
2000).
Leveraging RNAStructure to DesignChemical Probes of
Function
The most challenging aspect of targeting RNA structural motifs
with chemical probes is achieving the required level of specificity
in the presence of high concentrations of bystander RNAs. rRNA
and tRNA comprise 80% and 15% of total cellular RNA,
respectively; the level of an individual mRNA is <1% (Johnson
et al., 1975, 1977). Thus, from an abundance standpoint, a given
structured RNA motif is most likely to be found in rRNA or tRNA.
A modular approach in which multiple motifs are targeted simul-
taneously is one manner to overcome this problem (Figure 6C).
That is, selectivity is much improved with a multivalent com-
pound because, although there may be a large number of single
targetable RNA motifs in the transcriptome, there are far fewer
RNAs that have two targetable sites separated by a specific dis-
tance (Kumar et al., 2011a).
Pathogenic RNAs are traditionally targeted with antisense
oligonucleotide probes. RNAs that are highly structured, how-
ever, are difficult to target with antisense oligonucleotides as
the target RNA’s structure must first be unfolded. In contrast,
small molecules are more apt to bind structured RNAs by bind-
ing to discrete motifs. Development of RNA-targeting small
molecules has long been hampered by absence of rational
principles of ligand design. Structure-based approaches have
been complicated by RNA’s high flexibility and low barrier for dy-
namic rearrangement of secondary structure elements. High
throughput screening libraries are optimized for protein targets,
leading to low hit rates in RNA-targeting screening campaigns.
Despite these challenges, significant advances have been
made in the development of small molecules that target RNA
Neuron
Review(Disney, 2013; Disney et al., 2014; Gallego and Varani, 2001;
Guan and Disney, 2012; Shortridge and Varani, 2015; Thomas
and Hergenrother, 2008; Velagapudi et al., 2014). Below, we
summarize the present state of the development of chemical
tools to study structured RNAs and to target it therapeutically.
Identifying and Designing Chemical Probes
Several key advances have pushed the RNA-targeting field for-
ward such as those in RNA structural biology, structure-based
approaches including modeling of dynamic ensembles, and
identification of RNA-binding modules (Batey et al., 2004;
Childs-Disney et al., 2014; Davidson et al., 2009; Disney, 2013;
Disney et al., 2014; Gallego and Varani, 2001; Jahromi et al.,
2013a; Lee et al., 2010; Montange and Batey, 2006; Ofori
et al., 2012; Palde et al., 2010; Parkesh et al., 2011; Shortridge
and Varani, 2015; Stelzer et al., 2011; Trausch et al., 2011; Yil-
dirim et al., 2013). High-resolution structures of ribosomes and
other RNA-protein complexes combined with modeling of RNA
dynamics have enabled structure-based approaches to develop
new antibiotics and antivirals. Such studies have also enabled a
fragment-based approach to drug design (Garavı´s et al., 2014).
We recently reported a computational approach to design small
molecules that bind RNA named Inforna (Velagapudi et al.,
2014). Inforna uses a database of privileged RNA motif-small
molecule interactions derived from a small molecule library-
versus-RNA motif library screen (2-Dimensional Combinatorial
Screening [2DCS] [Childs-Disney et al., 2007; Disney et al.,
2008]). This approach opens a new opportunity to overcome
the selectivity problem of RNA-targeting small molecule ligands.
While the number of structural building blocks is limited for RNA
and targetable motifs can be present in many cellular RNAs, the
probability of co-localization of two structural motifs in close
proximity is much lower (see discussion in Kumar et al.,
2011a). We demonstrated that a modular assembly approach
using multivalent compounds that bind two motifs in close prox-
imity increases selectively and potency (Lee et al., 2009a; Push-
echnikov et al., 2009; Tran et al., 2014). Modular assembly is
particularly attractive for targeting expanded repeats because
of their own modular organization; by combining several
identical RNA-targeting fragments in one molecular entity, a sig-
nificant gain in affinity and selectivity can be achieved (Childs-
Disney et al., 2012a) (Figure 6C). Unfortunately, as the valency
of modularly assembled compounds increases, so does molec-
ular weight, which hampers cellular permeability. To solve this
problem, we demonstrated that a pathogenic RNA could tem-
plate the assembly of RNA-targeting oligomers inside cells, us-
ing a disease-causing RNA as a catalyst for inhibitor synthesis
at the required site of action (Rzuczek et al., 2014) (Figure 6C).
Another challenge in designing chemical probes for RNA is
validation of a target in vivo. Techniques developed for resolving
RNA-protein interactions (CLIP, iCLIP, etc.) are not directly appli-
cable to small molecules. To solve this problem, we developed a
technique named chemical cross-linking and isolation by pull-
down (Chem-CLIP) (Guan and Disney, 2013). It is based on
selective covalent modification of a target RNA by attaching a
reactive module and biotin to an RNA-binding scaffold. Reacted
RNAs are subsequently captured with streptavidin-coated
beads and analyzed by qRT-PCR. Extension of this technique
termed Chem-CLIP-Map allows one to locate the binding siteof the small molecule (Yang et al., 2015). After reaction in cells,
total RNA is treated with an antisense oligonucleotide and
RNase H. Cleaved RNA fragments that reacted with the small
molecule are then isolated with streptavidin beads, thereby
establishing the region of the mRNA to which small molecule
binds (Yang et al., 2015).
Targeting the RNAs that Cause the Myotonic
Dystrophies
Several approaches have been used to improve downstreamde-
fects caused by r(CUG)exp (DM1). To inhibit inclusion of exon 7a
in CLCN1 mRNA, a 25-mer morpholino antisense oligonucleo-
tides (ASO) targeting CLCN1 30 and 50 splice sites were adminis-
tered to transgenic mice expressing r(CUG)250 in the 3
0 UTR of
human skeletal actin gene (HSALR mice [Mankodi et al., 2002]).
The oligonucleotides improved splicing of CLCN1 and elimi-
nated associated channelopathy (Wheeler et al., 2007). Similar
effects together with correction of other DM1-associated pathol-
ogies were achieved with other 25-mer morpholino ASO target-
ing r(CUG)exp in the same mouse model of DM1 (Wheeler et al.,
2009, 2012). The ASO corrected splicing of MBNL1-dependent
mRNAs but also downregulated the Taxilin beta (Txlnb) gene,
which contains r(CUG)9. Finally, phase I and II clinical trials of a
gapmer targeting mutant DMPK mRNA has been recently initi-
ated (Isis Pharmaceuticals, 2014). A number of small-molecule
probes have also been developed for targeting r(CUG)exp that
displace MBNL1 and improve downstream defects (Arambula
et al., 2009; Childs-Disney et al., 2012a, 2012b, 2013; Hoskins
et al., 2014; Jahromi et al., 2013a, 2013b; Parkesh et al., 2012).
These compounds were either identified from screening, de-
signed from the structure of r(CUG) repeats, or designed from
privileged RNA motif-small molecule interactions including
modularly assembled compounds thereof.
Several examples of small molecules that target r(CCUG)exp
and improve DM2-associated defects have been reported
(Childs-Disney et al., 2014; Lee et al., 2009b; Nguyen et al.,
2014; Rzuczek et al., 2014). Our group reported that the amino-
glycoside kanamycin A selectively binds 23 2 50CU30/30UC50 in-
ternal loops. From the X-ray structure and molecular dynamics
simulations, we identified that dynamic equilibrium between
two conformations facilitates recognition of the small molecule.
Once bound, a kanamycin derivative stabilizes one conforma-
tional state of the loop, thereby stabilizing the whole structure
(Childs-Disney et al., 2014). When assembled into dimers and
higher-order oligomers, kanamycin exhibited high affinity and
selectivity for r(CCUG) repeats (Lee et al., 2009a) and improved
DM2-associated defects in a cellular model (Childs-Disney
et al., 2014). During the course of our in cellulo studies, the struc-
ture of r(CCUG) repeats was refined and the binding of a dimeric
kanamycin ligand modeled (Childs-Disney et al., 2014). This
enabled the design of a kanamycin derivative that oligomerized
in cellulo upon binding to r(CCUG)exp (Rzuczek et al., 2014).
The derivative contained both azide and alkyne groups that
were precisely positioned within the aminoglycoside as deter-
mined by modeling studies. Upon binding adjacent 50CU30/
30UC50 in r(CCUG)exp, the alkyne group of one kanamycin is
brought into close proximity to the azide group of an adjacent
kanamycin. The otherwise unreactive groups react to form a sta-
ble triazole via a Huisgen dipolar cycloaddition reaction, a variantNeuron 87, July 1, 2015 ª2015 Elsevier Inc. 37
Neuron
Reviewof click chemistry (Kolb et al., 2001). The in cellulo assembled
oligomers exhibited potency (nM) far greater thanpre-assembled
oligomers and assembly only occurs in DM2-affected cells, not in
healthy cells (Rzuczek et al., 2014). These studies also advance a
new strategy in drug design, where a drug is synthesized on-site
by using disease affected cell as a reaction vessel and a disease
causing biomolecule as a drug synthesis catalyst (Figure 6C).
Targeting r(CGG)exp, a Pathogenic Agent in FXTAS
and FXS
Following the same rational approach to the design of ligands
targeting r(CUG)exp and r(CCUG)exp, our group has developed
selective compounds that target r(CGG)exp in both FXTAS and
FXS (Colak et al., 2014; Disney et al., 2012; Tran et al., 2014).
The small molecule 1a was identified to bind 50CGG30/30GGC50
using chemical similarity searching of a known RNA binder
(Disney et al., 2012). A high-throughput FRET-based screen
was used to identify compounds that disrupt the binding of
r(CGG) repeats to an RNA-binding protein (DGCR8D) (Disney
et al., 2012). Small molecule 1a inhibits formation of nuclear
foci and improves FXTAS-associated alternative pre-mRNA
splicing defects (Disney et al., 2012). Importantly, 1a was
essential in elucidating the mechanism of FMRP silencing in
FXS (Colak et al., 2014). The molecule stabilizes r(CGG)exp and
prevents its unfolding—a crucial step in formation of the RNA-
DNA hybrid that leads to inhibition of gene expression (Colak
et al., 2014).
Modular assembly of a benzimidazole derivative that binds
50CGG30/30GGC50 also improves FXTAS-associated defects
(Tran et al., 2014). Notably, binding of the compound to
r(CGG)exp in cellulo does not affect translation of a downstream
open reading frame (ORF). This is significant as the FMR1 ORF
encodes FMRP, the loss of which causes FXS. An antisense
oligonucleotide also improves FXTAS-associated defects but in-
hibits translation of the downstream ORF (Tran et al., 2014). The
analogous molecule that binds r(CGG)exp irreversibly, via the
installation of a nucleic acid-reactive group, inhibits RAN trans-
lation and normalizes alternative pre-mRNA splicing patterns
(Yang et al., 2015). In contrast to antisense oligonucleotide tar-
geting r(CGG)exp, the molecule did not affect loading of ribo-
somes onto mRNA or inhibit translation of the downstream
ORF. By using a reactive compound, the binding sites for the
small molecules were mapped to r(CGG)exp in cells using
Chem-CLIP-Map (Yang et al., 2015).
Small Molecule Probes of r(G4C2)exp in c9ALS/FTD
Interestingly, the structures of r(CGG)exp and r(G4C2)exp have a
shared motif—1 3 1 nucleotide GG internal loops. We therefore
completed a chemical similarity search of 1a to construct a li-
brary of small molecules that might bind r(G4C2)exp and alleviate
ALS-associated symptoms. We identified three small molecules
that bind r(G4C2)exp in cellulo (via Chem-CLIP), two of which
inhibit r(G4C2)exp foci formation and RAN translation in c9ALS
cellular model, including patient-derived iNeurons (Su et al.,
2014). One was further tested in ALS patient-derived cells
(iNeurons) and shown to be bioactive (Su et al., 2014). In another
study, a porphyrin-derived G-quadruplex binder, TMPyP4, was
shown in vitro to disrupt G-quadruplexes formed by r(G4C2)exp
and to inhibit its interaction with RNA-binding proteins in vitro
(Zamiri et al., 2014).38 Neuron 87, July 1, 2015 ª2015 Elsevier Inc.Targeting MAPT Mutations
As aforementioned,MAPTmutations can cause de-stabilization
of RNA secondary structure, leading to deregulation of alterna-
tive splicing via altered interaction with U1 snRNP (Jiang et al.,
2000). Stabilization of the RNA’s structure restores normal
splicing patterns (Donahue et al., 2006) (Figure 7). A high-
throughput, FRET-based screen identified that the intercalator
mitoxantrone (MTX, LDN-13978) stabilizes the mutated MAPT
hairpin (Donahue et al., 2007). Importantly, mere intercalating
ability is not sufficient for stabilization (Donahue et al., 2007). A
structural study of MTX complexed with the MAPT hairpin by
NMR spectroscopy revealed that MTX binds the bulge region
of the stem-loop (Zheng et al., 2009). A number of attempts
were made to optimize MTX by means of classic medicinal
chemistry (Liu et al., 2009; Zheng et al., 2009) or conjugating it
to aminoglycosides (Artigas and Marcha´n, 2015; Artigas et al.,
2015). In addition, alternative chemotypes were actively sought
via dynamic combinatorial chemistry (Lo´pez-Senı´n et al., 2011;
Ofori et al., 2012), and ‘‘Janus’’-type compounds were designed
to recognize the GU wobble base pair created by the mutations
(Artigas and Marcha´n, 2013).
By using Inforna, a compound was identified by our laboratory
that binds to the A-bulge in the MAPT mutant RNA hairpin (Luo
and Disney, 2014). The molecule binds the same A-bulge, which
was targeted by MTX, and increases thermal stability of the
mutantMAPT hairpin but not of the wild-type (Figure 7). Mutation
of the A-bulge to an AU pair ablates small-molecule binding, thus
indicating secondary structure-specific mode of action (Luo and
Disney, 2014). The compound also affects exon 10 inclusion in
cellular models of disease.
Targeting IRE-like Hairpins in Alzheimer’s and
Parkinson’s Diseases
The free concentration of intracellular iron has a profound effect
on conformation of IREs in several mRNAs, including APP (Alz-
heimer’s disease [AD]) and a-synuclein (Parkinson’s disease
[PD]) (Friedlich et al., 2007; Rogers et al., 2011). The IRE-like hair-
pins regulate the expression level of the corresponding proteins
(Febbraro et al., 2012; Rogers et al., 2002). High-throughput
screening yielded a number of active compounds that regulate
iron-dependent APP (Bandyopadhyay et al., 2006) and a-synu-
clein (Rogers et al., 2011) expression levels. It is plausible that
an iron-dependent RNA conformational switch may serve as a
mechanistic link connecting iron levels and protein-induced pa-
thologies (Fine et al., 2015). Targeting the IRE-like hairpin directly
is thus an attractive alternative therapeutic option in AD and PD.
Summary and Conclusions
The expanding functions of ncRNAs open up new opportunities
for drug discovery. Structural biology and biophysical studies
provide rational design principles for RNA-targeting ligands.
There is no doubt that the number of functionally active RNA
structural motifs will grow due to development of bioinformatic
tools, our expanding knowledge of RNA structural biology, and
the sheer size and diversity of the human genome. At the same
time, the complexity of newly discovered RNA regulatory net-
works poses a significant challenge on the validation of
bioinformatic transcriptome-wide analyses, and hence on the
design of selective chemical tools and therapeutics. Variable
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Reviewtissue-specific patterns of pre-mRNA splicing, emerging func-
tional role of RNA localization, as well as complex tangles of
feedback loops are just few examples of ‘‘known unknowns’’
of RNA cellular biology. In addition, despite substantial
progress in understanding of RNA biochemistry, biophysics
and structure, the relevance of these discoveries for in vivo
biology remains disputable and requires rigorous validation.
Nevertheless, in our opinion, it is an unaffordable luxury to
disregard RNA as a potential drug target. Various therapeuti-
cally relevant structured ncRNA targets were outlined in this
Review, and strategies for targeting them provide a broad range
of opportunities in drug development for currently incurable
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